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Parkinson’s disease (PD) becomes increasingly common with advancing age. It is therefore 
possible that cell senescence contributes to its pathophysiology. In a recent paper in Cell 
Reports, Chinta et al1 have shown that astrocytes exhibiting an age-associated (senescent) 
phenotype are toxic to neurons in vitro, and their removal is associated with better 
outcomes in a mouse model of PD. This finding may be relevant to other neurodegenerative 
conditions such as Alzheimer’s and Amyotrophic Lateral Sclerosis (ALS) in which cellular 
senescence is also implicated.2 
 
Cellular senescence is not necessarily deterimental.3 It involves the termination of cell 
growth, followed by development of a senescence-associated “secretory” phenotype (SASP) 
that recruits immune cells such as macrophages.3 Nearby progenitor cells are then 
prompted to engage in repair.3 In the context of tissue damage this is initially helpful, but 
can lead to further damage once clearance mechanisms are saturated. 
 
In post-mortem tissue from the substantia nigra of 5 PD patients and 5 controls, Chinta et al 
show that PD astrocytes have higher expression of senescence markers and elevated levels 
of inflammatory cytokines and metalloproteinases associated with a SASP. In human cell 
culture models, astrocytes and fibroblasts show a more senescent phenotype when exposed 
to paraquat, a herbicide associated with PD risk, and this is associated with the production 
of factors, including IL-6, which are toxic to dopaminergic neurons. In a mouse model in 
which senescent astrocytes are selectively depleted, neurodegeneration is attenuated in 
response to paraquat, with better performance on motor tasks and decreased nigral 
dopaminergic cell loss.1  
 
These findings raise the interesting possibility that astrocyte senescence contributes to PD 
pathology and as such could represent a novel target for disease-modifying therapy. 
However, toxin-based models have important limitations in terms of their ability to replicate 
the pathology of idiopathic PD, and such models have not been successful to date in 
identifying effective therapeutic targets.  Another important consideration is whether the 
relevance of astrocyte senescence is restricted to the early pathological stages of PD– in 
which case ‘real-world’ disease may present too late for astrocyte modification to succeed 
as a therapeutic strategy. Hence the critical question to now be addressed is whether 
astrocyte senescence is associated with faster clinical progression of PD. PET ligands to 
image reactive astrocytes in vivo are now in development,4 which, in conjunction with CSF 
markers of the SASP, may facilitate such studies of the natural history of astrocyte 
senescence in PD. 
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